Quintiles and Movetis Announce Strategic Alliance to Launch Gastrointestinal Product

RESEARCH TRIANGLE PARK, N.C. & TURNHOUT, Belgium, Jan, 31, 2010 (Business Wire / ME NewsWire): Quintiles today announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany. Under the alliance, Quintiles will execute a comprehensive commercial sales effort for the product launch and provide additional services in consulting, market access, market intelligence and analytics, regulatory and post-marketing pharmacovigilance. The agreement is expected to be extended later this year to cover other selected European countries.
Movetis is a European specialty pharmaceutical company focused on the discovery, development and commercialization of proprietary and innovative drugs for the treatment of diseases in the gastrointestinal (GI) area. Movetis obtained approval for the commercialization of Resolor in the European Economic Area for the symptomatic treatment of chronic constipation for women in whom laxatives fail to provide adequate relief.
Chris Pepler, Senior Vice President of Global Business Development and Operations for Quintiles said: “This agreement is an example of how leading specialty pharma companies are building partnerships that extend beyond the traditional Commercial Sales Organization model to manage risk, increase productivity, overcome complexity and demonstrate value to stakeholders in the New Health. We are pleased that Movetis has chosen to leverage Quintiles’ suite of comprehensive services, including our product and brand solutions, to help ensure the commercial success of Resolor.”
Movetis CEO Dirk Reyn said: “We are confident that our alliance with Quintiles will help drive our goal of becoming a successful European specialty GI company. The launch of Resolor will be a key milestone as we continue to build on our expertise in bringing new GI drugs from discovery to marketing.”